Last updated: August 1, 2026
Nitrofurazone is an established topical nitrofuran antibacterial with no meaningful active clinical-development program, no identifiable modern composition-of-matter patent barrier, and limited commercial growth prospects. Its market is concentrated in low-cost generic topical products, veterinary applications, and selected hospital or specialty wound-care uses. Clinical-trial activity is negligible, while regulatory and safety restrictions limit expansion into food-producing animals and new human indications.
What is nitrofurazone used for?
Nitrofurazone is a synthetic nitrofuran antimicrobial used primarily as a topical cream, ointment, solution, or soluble dressing. It inhibits bacterial enzymes after intracellular reduction of the nitrofuran group, damaging bacterial proteins and DNA.
Human uses have included:
- Topical treatment or prevention of bacterial infection in burns
- Skin-graft donor and recipient sites
- Superficial skin infections
- Wound care where susceptible organisms are present
Veterinary uses have included:
- Bacterial infections in horses and other companion animals
- Wound and burn treatment
- Mastitis-related applications in some jurisdictions
- Topical treatment of infected skin lesions
Nitrofurazone is not a systemic antibiotic and is not a substitute for systemic therapy in deep, invasive, or rapidly progressing infections. Commercial products commonly use a concentration near 0.2%, although product availability and labeling differ by country.
What is the current FDA status of nitrofurazone?
Nitrofurazone has a long history of U.S. marketing in human and veterinary topical products. Current availability is fragmented, with products marketed by generic manufacturers, compounding pharmacies, veterinary suppliers, and international manufacturers.
Human regulatory status
The historical human product Furacin was marketed as a topical nitrofurazone product. The U.S. product landscape has changed over time, and several historical branded products have been discontinued or are no longer actively marketed. Nitrofurazone products may remain available through generic, hospital, specialty, or compounded channels.
The FDA label history identifies topical use for susceptible bacterial infections in burns and skin-graft sites. Nitrofurazone is not a new molecular entity and does not have modern clinical-development exclusivity.
The most relevant regulatory issues are:
- Product-specific approval status
- Whether the product is actively marketed
- Prescription versus veterinary distribution
- Compounding status
- Country-specific restrictions
- Labeling concerning hypersensitivity and prolonged exposure
Veterinary regulatory status
Nitrofurazone has a substantial veterinary history. U.S. animal-drug regulation is important because nitrofurazone and other nitrofurans have been restricted in food-producing animals due to carcinogenicity and residue concerns.
The FDA prohibits extralabel use of nitrofurans in food-producing animals under the prohibited animal-drug provisions. This limits commercial use in cattle, swine, poultry, and other animals entering the human food chain. Companion-animal and equine uses face a different regulatory framework, but products must still comply with labeling and veterinary-prescription requirements.
Are there active clinical trials for nitrofurazone?
No active late-stage or modern registration-directed clinical program is evident for nitrofurazone. ClinicalTrials.gov contains historical or investigator-led records involving topical antimicrobials and wound treatment, but nitrofurazone does not have a current development profile comparable with modern antibiotics, antimicrobial peptides, biologics, or advanced wound-care products. [1]
Clinical-trial status
| Development category |
Current status |
| Phase 1 studies |
No active commercial program identified |
| Phase 2 studies |
No active commercial program identified |
| Phase 3 studies |
None identified |
| Registration-enabling trials |
None identified |
| Pediatric development |
No active program identified |
| New delivery-system trials |
No established program identified |
| Veterinary clinical development |
Product-specific and local, not a major global program |
The evidence base is primarily historical clinical use, older comparative studies, product labeling, and localized wound-care experience. The absence of a contemporary development program reflects the molecule's age, low commercial price, established generic competition, and safety concerns.
What clinical evidence supports nitrofurazone?
Historical use supports topical antibacterial activity in selected wound and burn settings. The evidence is less robust than the evidence generated for contemporary wound-care products and does not establish a broad superiority claim over modern topical antibiotics, antiseptics, silver-based products, or advanced dressings.
Clinical limitations include:
- Limited contemporary randomized evidence
- Lack of large modern trials using current wound-care standards
- Risk of allergic contact dermatitis
- Potential selection for resistance
- Limited value against resistant organisms without susceptibility evidence
- Lack of systemic exposure data for extensive or damaged skin
- Inadequate evidence for chronic wound indications such as diabetic foot ulcers
Nitrofurazone is therefore more accurately classified as a legacy topical antimicrobial than as an active clinical-stage drug.
What patents protect nitrofurazone?
The original nitrofurazone molecule is long off patent. Any original composition-of-matter patent would have expired decades ago. The commercial product is not protected by a current foundational patent estate.
Patent position
| IP category |
Commercial significance |
| Nitrofurazone composition of matter |
Expired |
| Original antibacterial use claims |
Expired or unenforceable by age |
| Basic topical formulations |
Generally public-domain technology |
| Modern delivery systems |
Potentially patentable if independently developed |
| Combination products |
May have product-specific protection |
| Manufacturing processes |
Could be protected only if novel and non-obvious |
| Generic 0.2% ointment or cream |
No meaningful molecule-level barrier |
No current patent should be presumed to block a conventional nitrofurazone cream, ointment, or solution solely because it contains nitrofurazone. Commercial protection would instead depend on formulation engineering, packaging, combination therapy, manufacturing know-how, or regulatory exclusivity.
Are formulation patents relevant?
Formulation patents could matter if a company developed a differentiated product such as:
- A controlled-release wound dressing
- A hydrogel or nanofiber delivery system
- A combination with a modern antiseptic or anti-inflammatory agent
- A non-irritating formulation with improved tolerability
- A product designed for prolonged wound residence
- A sterile ready-to-use hospital dressing
Such claims would need to protect more than the known use of nitrofurazone in a topical base. A conventional petrolatum ointment, cream, or aqueous solution would face a weak patent position because the underlying dosage forms are established and readily reproducible.
What is the Orange Book status of nitrofurazone?
Nitrofurazone does not have the Orange Book profile associated with an actively protected branded drug. The Orange Book is primarily relevant to approved prescription drug products and listed patents or exclusivity connected with those products. [2]
The commercial implications are:
- No current reference-product patent wall comparable with protected branded drugs
- No meaningful five-year new-chemical-entity exclusivity
- No active pediatric exclusivity platform
- No modern 30-month litigation framework centered on a major branded product
- Generic or abbreviated approval pathways may depend on the specific product and dosage form
A product marketed through a compounding route may not have the same regulatory status as an FDA-approved finished dosage form. Buyers and licensors must distinguish among an approved prescription product, an animal drug, a compounded preparation, and an imported product.
Have there been Paragraph IV challenges or patent litigation?
No major current Paragraph IV campaign or commercially material patent litigation involving nitrofurazone is identifiable. The molecule's age and generic availability reduce the economic incentive for both branded patent litigation and large-scale generic challenges.
Litigation exposure
| Risk category |
Current assessment |
| Active composition-of-matter litigation |
Low |
| Active formulation litigation |
Low |
| Paragraph IV activity |
No major current campaign identified |
| ANDA litigation exposure |
Low |
| Trade-secret exposure |
Possible in specialized manufacturing |
| Trademark disputes |
Possible at product level |
| Regulatory enforcement |
More relevant than patent litigation |
The main legal risks concern product quality, labeling, compounding, importation, veterinary use, residue control, and promotional claims. A company launching a conventional product is more likely to face regulatory or commercial scrutiny than an infringement suit based on an active nitrofurazone patent.
What companies manufacture or market nitrofurazone?
Nitrofurazone is supplied by a dispersed group of generic pharmaceutical companies, veterinary-drug manufacturers, contract manufacturers, compounding pharmacies, and active pharmaceutical ingredient suppliers. Product names and market participants vary by jurisdiction.
Historical and current commercial channels have included:
- Generic human topical manufacturers
- Veterinary pharmaceutical companies
- Hospital-supply distributors
- Equine-care suppliers
- Compounding pharmacies
- Regional pharmaceutical companies in Latin America, Asia, the Middle East, and other markets
The market is not controlled by a single global innovator. Brand recognition is more important in veterinary channels than in human generic channels, where purchasing decisions usually depend on price, availability, quality, formulation, and institutional procurement contracts.
How large is the nitrofurazone market?
No widely accepted public database reports a standalone, audited global nitrofurazone market. Commercial reports that publish market figures often combine nitrofurazone with broader categories such as topical antibiotics, wound-care products, veterinary antimicrobials, or nitrofuran drugs. Those figures should not be treated as nitrofurazone-specific revenue.
Market structure
The largest demand pools are likely to be:
- Veterinary topical products, especially equine and companion-animal use
- Low-cost human topical products in markets where nitrofurazone remains labeled
- Hospital and surgical wound-care procurement
- Compounding and specialty pharmacy supply
- Regional products in countries with less restrictive legacy-drug markets
The product has limited pricing power. A standard generic ointment is generally interchangeable with other topical antibacterial products, subject to labeling, supply, and clinician preference.
Commercial strengths
- Low-cost active ingredient
- Established manufacturing knowledge
- Long history of topical use
- Simple dosage forms
- Existing veterinary demand
- Low clinical-development expense
Commercial weaknesses
- No meaningful patent protection
- Limited clinical differentiation
- Generic price competition
- Allergy and tolerability concerns
- Restrictions in food-producing animals
- Competition from silver sulfadiazine, mupirocin, fusidic acid, bacitracin, povidone-iodine, chlorhexidine, and advanced wound dressings
- Limited reimbursement upside
- Variable product availability by country
What is the projected nitrofurazone market growth?
The base-case outlook is flat to modestly declining for conventional human products and stable to modestly growing for selected veterinary and specialty formulations.
Because no audited standalone market baseline is available, the following is a scenario projection rather than reported market revenue.
| Scenario |
2024-2030 annual growth |
Main assumptions |
| Downside |
-4% to -7% |
Continued generic substitution, declining human use, tighter antimicrobial controls |
| Base case |
-1% to +2% |
Stable veterinary demand offsets lower human utilization |
| Upside |
+3% to +6% |
New wound-care delivery system, regional expansion, or veterinary product innovation |
The base case implies a mature market with little volume expansion and limited ability to raise price. Growth would need to come from geographic penetration, private-label supply, veterinary channel expansion, or a differentiated delivery system rather than from broader clinical adoption of conventional ointments.
Revenue exposure by channel
| Channel |
Direction through 2030 |
Commercial view |
| Human generic ointments |
Declining or flat |
High substitution and low pricing |
| Hospital burn care |
Flat |
Dependent on formulary status and alternatives |
| Companion animals |
Stable |
Demand supported by established veterinary use |
| Equine products |
Stable to modest growth |
Brand and practitioner loyalty can support margins |
| Food-producing animals |
Restricted |
Regulatory limits constrain expansion |
| Advanced wound-care formulations |
Potential growth |
Requires new clinical and IP investment |
How does nitrofurazone compare with competing topical antimicrobials?
Nitrofurazone competes in a crowded category with different regulatory and clinical profiles.
| Product |
Primary position |
Competitive effect on nitrofurazone |
| Mupirocin |
Human topical antibacterial |
Stronger modern prescribing position in selected skin infections |
| Fusidic acid |
Human topical antibacterial |
Strong regional competition outside the U.S. |
| Silver sulfadiazine |
Burns and wound care |
Direct competition in burn treatment |
| Bacitracin combinations |
Consumer and prescription topical use |
Low-cost substitution |
| Povidone-iodine |
Broad antiseptic use |
Competes in wound and procedural settings |
| Chlorhexidine |
Skin antisepsis |
Competes for prophylactic use |
| Advanced dressings |
Chronic and complex wounds |
Higher-value alternative with clinical differentiation |
| Systemic antibiotics |
Deep or invasive infection |
Replaces topical therapy when infection is extensive |
Nitrofurazone's strongest competitive position is in legacy, low-cost, topical, or veterinary use. Its weakest position is in indications requiring contemporary comparative evidence, antimicrobial-stewardship support, or premium reimbursement.
What generic launch scenarios exist for nitrofurazone?
A conventional generic launch would face low technical barriers but limited commercial upside.
Scenario 1: Standard topical generic
A manufacturer launches a 0.2% ointment or cream using a conventional base. The product can compete on price and supply reliability. Expected barriers are regulatory documentation, product-quality validation, sterile or microbiological controls where applicable, and market access.
Scenario 2: Veterinary private-label product
A company supplies nitrofurazone to veterinary distributors under private-label arrangements. This route may provide better commercial economics than human generic sales because of brand segmentation and specialist distribution.
Scenario 3: Hospital wound-care formulation
A manufacturer develops a ready-to-use sterile product or dressing. This has greater differentiation potential but requires clinical support, formulation work, packaging validation, and potentially a new regulatory submission.
Scenario 4: Combination or advanced delivery product
A company combines nitrofurazone with a wound-healing material, controlled-release matrix, or another antimicrobial. This is the only scenario with a credible path to meaningful new IP, but the development risk is materially higher than for a standard generic.
What manufacturing and IP barriers affect nitrofurazone?
The active ingredient itself is not the principal barrier. Manufacturing barriers arise from product quality and dosage-form execution.
Key requirements include:
- API identity, assay, and impurity control
- Control of nitrofuran-related impurities
- Uniform drug distribution in semisolid products
- Microbial limits and preservative performance
- Container-closure compatibility
- Stability under heat and light exposure
- Batch-to-batch viscosity and rheology control
- Validation of sterile processing when required
- Supply-chain compliance for API and excipients
A company seeking a defensible position would need to invest in formulation performance, tolerability, clinical evidence, or distribution rather than rely on the old molecule's patent history.
What licensing opportunities exist for nitrofurazone?
Licensing opportunities are more likely to involve products and channels than the molecule itself.
Potential transaction structures include:
- Regional rights for an approved human topical product
- Veterinary private-label supply agreements
- API supply and contract manufacturing
- Hospital procurement contracts
- Licensing of a wound dressing that incorporates nitrofurazone
- Combination-product rights
- Geographic registration transfers
Large upfront payments are unlikely for conventional nitrofurazone. Deal value would depend on regulatory status, manufacturing capacity, geographic rights, exclusivity of supply, and evidence of recurring institutional or veterinary demand.
Key Takeaways
- Nitrofurazone has no active modern clinical-development program of commercial significance.
- The molecule is long off patent, and conventional topical products face no meaningful composition-of-matter barrier.
- The Orange Book and Paragraph IV landscape is limited and does not resemble that of an actively protected branded medicine.
- Veterinary and regional generic markets are more commercially relevant than innovative human pharmaceutical development.
- Food-animal restrictions materially limit veterinary expansion.
- Standard human topical products are likely to remain flat or decline through 2030.
- The best growth opportunity is a differentiated wound-care delivery system, veterinary private-label platform, or regional supply strategy.
- Patent value would come from a new formulation, combination, delivery device, or manufacturing process, not from nitrofurazone itself.
- Regulatory compliance, product quality, supply reliability, and channel access are more important than patent litigation risk.
FAQs
Is nitrofurazone still available in the United States?
Availability depends on the product, manufacturer, dosage form, and distribution channel. Human and veterinary products may be marketed differently, and some products are available through specialty or compounding channels rather than broad retail distribution.
Is nitrofurazone approved for diabetic foot ulcers?
Nitrofurazone does not have a widely recognized modern FDA approval specifically for diabetic foot ulcers. Evidence and labeling for chronic wound use should be evaluated separately from historical burn and superficial-wound indications.
Can nitrofurazone be used in food-producing animals?
U.S. regulations prohibit extralabel use of nitrofurans, including nitrofurazone, in food-producing animals because of residue and safety concerns. Veterinary use must be assessed under the rules of the relevant jurisdiction.
Does nitrofurazone have biosimilar competition?
No. Nitrofurazone is a small-molecule chemical drug, not a biologic. The relevant competition is from generic topical products, veterinary products, antiseptics, and alternative wound-care technologies.
Is nitrofurazone commercially attractive for a pharmaceutical company?
A standard generic product offers limited upside because of low pricing, mature demand, and competition. Commercial attractiveness improves if the company has a differentiated wound-care formulation, protected delivery technology, veterinary distribution, or a low-cost regional manufacturing platform.
References
-
ClinicalTrials.gov. (2024). Search results for nitrofurazone clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=nitrofurazone
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Animal drugs, feeds, and related products. https://www.fda.gov/animal-veterinary
-
U.S. Food and Drug Administration. (2024). 21 CFR ยง 530.41: Drugs prohibited for extralabel use in animals. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-530
-
National Library of Medicine. (2024). DailyMed: Nitrofurazone topical product labeling. https://dailymed.nlm.nih.gov/dailymed/
-
World Health Organization. (2019). Critically important antimicrobials for human medicine, 6th revision. World Health Organization. https://www.who.int/publications/i/item/9789241515528
